DiamiR Biosciences Corp. (DIMR)

DiamiR Biosciences was planning to go public, but the IPO was withdrawn on Jul 14, 2025.

Stock Price: Pending

IPO price not available yet

DiamiR Biosciences Financials Overview

Financials in millions USD. Fiscal year is June - May.

Millions USD. Fiscal year is Jun - May.

Revenue & Profits

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Feb '24 Feb 29, 2024	May '23 May 31, 2023	May '22 May 31, 2022
Revenue	1.32	1.13	1.44
Revenue Growth	-	-21.71%	-
Gross Profit	1.32	1.13	1.44
Operating Income	-0.5	-1.16	-0.16
Net Income	-0.63	-1.32	-0.32

Fiscal Year	Current	FY 2023	FY 2022
Period Ending	Feb '24 Feb 29, 2024	May '23 May 31, 2023	May '22 May 31, 2022
Cash & Investments	0.14	0.18	0.29
Total Debt	0.59	0.46	1.05
Net Cash (Debt)	-0.44	-0.28	-0.76
Net Cash Growth	-	-	-

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Feb '24 Feb 29, 2024	May '23 May 31, 2023	May '22 May 31, 2022
Operating Cash Flow	-0.24	-0.21	0.12
Capital Expenditures	-0	-	-0
Free Cash Flow	-0.24	-0.21	0.12
Free Cash Flow Growth	-	-	-

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Feb '24 Feb 29, 2024	May '23 May 31, 2023	May '22 May 31, 2022
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-37.88%	-102.63%	-10.78%
Pretax Margin	-41.26%	-112.75%	-22.29%
Profit Margin	-47.98%	-116.88%	-22.29%
FCF Margin	-18.34%	-18.38%	8.36%